Buoyant Bayer ups key drug sales forecast
This article was originally published in Scrip
Bayer reported a fall in fourth-quarter earnings for 2013, but the company is ended its 150th anniversary year in celebratory mode by announcing ambitions for its key products and R&D in 2014. Notably, it has upped its guidance for peak sales of its four growth-driving recently launched medicines by more than a third to €7.5bn or more.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.